Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial

• Daniel Franjic,

  Roles Conceptualization, Investigation, Supervision, Writing – review & editing

  Affiliation Pfizer Inc, Groton, Connecticut, United States of America

  ⨯
• Robert J. Fountaine,

  Roles Supervision, Writing – review & editing

  Affiliation Pfizer Inc, Groton, Connecticut, United States of America

  ⨯
• Catherine Nalpas ,

  Roles Investigation, Supervision, Writing – review & editing

  * E-mail: catherine.nalpas@pfizer.com

  Affiliation Pfizer Inc, Paris, France

  https://orcid.org/0009-0002-2932-0115

  ⨯
• Budhaditya Goswami,

  Roles Data curation, Formal analysis, Writing – review & editing

  Affiliation Pfizer Inc, Chennai, India

  ⨯
• Terence Fullerton

  Roles Supervision, Writing – review & editing

  Affiliation Pfizer Inc, Groton, Connecticut, United States of America

  ⨯